India is widely known as the “Pharmacy of the World” due to its dominance in the global supply of affordable generic medicines, yet it earns far less revenue from pharmaceutical innovation compared to global leaders.
Enroll now for UPSC Online Course
Key Terms in India’s Pharmaceutical Sector
- Generic Medicines: Low-cost medicines produced after the patent of an original drug expires, containing the same active ingredient and providing the same therapeutic effect as the branded drug.
- Novel Drugs: Completely new medicines developed through original research, such as breakthrough treatments for diseases like cancer, where most of the pharmaceutical industry’s profits are concentrated.
- Clinical Trial Phases: Drug testing occurs in four stages:
- Phase one checks safety in healthy volunteers,
- Phase two and Phase three assess efficacy in patients, and
- Phase four monitors long-term safety after approval.
- First-in-Human Trial: A term used for Phase one clinical trials, where a new drug is administered to humans for the first time, primarily to assess safety, dosage range, and side effects.
- Investigator-Initiated Trial Framework: A regulatory model used in China where researchers can begin human trials without first requiring permission from a central regulator, leading to much faster drug development
|
Revenue Gap in India’s Pharma Sector
- Revenue Disparity: India’s pharmaceutical industry earns about $50 billion annually, while a single company like Merck & Co. generates around $64 billion.
- Generics vs Innovation: Indian firms mainly produce generic medicines, whereas global companies profit from patented innovative drugs.
- Value Concentration: The major share of profits lies in patent-protected drugs, limiting India’s revenue despite large production capacity.
Regulatory Bottlenecks in India’s Pharma Sector
- Approval Delays: Permission from the Central Drugs Standard Control Organisation (CDSCO) for Phase one clinical trials can take up to two years, compared to about thirty days in the United States.
- Central Drugs Standard Control Organisation (CDSCO) is India’s national regulatory body responsible for drug approvals.
- Institutional Capacity Limits: Applications are reviewed by the Subject Expert Committee (SEC), whose limited capacity creates a major approval bottleneck.
- Global Competitiveness Impact: Regulatory delays allow faster systems in the United States and China to complete trials earlier and commercialise innovations.
- Low Clinical Trial Activity: India conducts around forty Phase one trials annually, far fewer than about eight hundred in the United States and more than one thousand in China, constraining drug innovation.
Technological Potential and Artificial Intelligence in India’s Pharma Sector
- Strong Talent Base: India possesses a unique combination of expertise in computer science, artificial intelligence, and biology based medicine, creating strong potential for pharmaceutical innovation.
- Accelerated Drug Discovery: Artificial intelligence can perform research tasks that earlier took years within a few months, significantly speeding up drug discovery.
- Personalised Medicine Potential: Advanced technologies make it possible to develop personalised medicines tailored to an individual’s DNA.
Check Out UPSC CSE Books From PW Store
Proposed Solution for Regulatory Bottlenecks- Decentralisation Model of Australia
- Decentralised Approvals for Early Trials: Hospitals, medical colleges, and research institutions should be empowered to approve Phase one and Phase two clinical trials through their own local expert committees.
- Local Subject Expert Committee Structure: Each committee should include a doctor, researcher, pharmaceutical expert, and biostatistician to ensure scientific and clinical evaluation.
- Working Mechanism:
- Institution-level Approval: Pharmaceutical companies can approach the local SEC of any authorised hospital or research institute for trial approval.
- Regulatory Intimation: After approval, the institution only needs to inform the Central Drugs Standard Control Organisation, without requiring central clearance.
- No Legislative Change Required: The decentralised model can be implemented within the existing regulatory framework.
- International Precedent: A decentralised system has been followed in Australia for nearly thirty years and is considered a global gold standard for clinical trial approvals.
- Expected Benefits:
- Faster Approvals: Multiple local SECs would reduce the burden on the central regulator and speed up approvals.
- Improved Research Ecosystem: Institutions such as All India Institute of Medical Sciences, Apollo Hospitals, Indian Council of Medical Research and Council of Scientific and Industrial Research could become active centres for early stage drug trials.
Consequences of Inaction in India’s Pharma Regulation
- Neglect of Local Diseases: Global pharmaceutical firms show limited interest in diseases that primarily affect India, such as tuberculosis and oral cancer, meaning lack of domestic innovation could prolong public health burdens.
- Geopolitical Dependency: Without strengthening innovation capacity, India may remain dependent on Western countries and China for new patented and expensive medicines.
- Biosecurity Risks: As artificial intelligence increases the possibility of creating new pathogens, a slow regulatory system could hinder India’s ability to rapidly develop medical countermeasures and respond to emerging biological threats.
Conclusion
India’s pharma talent is world-class, and adopting a decentralised regulatory model similar to that of Australia can help transform India from a generic drug manufacturer to a global innovator of novel medicines.
1 Apr 2026
.png)
Current Affairs
GS Foundation
Optional Course
Combo Courses
Degree Program
